Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C...

Area of Science:

• Cardiology
• Biochemistry
• Preventive Medicine

Background:

• Residual cardiovascular disease (CVD) event risk is a significant clinical challenge, even after effective low-density lipoprotein cholesterol (LDL-C) reduction with statins.
• Lipoprotein heterogeneity, characterized by abnormal lipoprotein size and density distribution, is a key contributor to this residual risk.
• Despite decades of research, the clinical utility of measuring lipoprotein heterogeneity remains debated.

Purpose of the Study:

• To highlight the unmet clinical need for identifying patients with significant residual CVD risk.
• To emphasize the role of lipoprotein heterogeneity in CVD pathogenesis and risk prediction.
• To underscore the clinical relevance and utility of assessing LDL subclass distribution.

Main Methods:

• Review of historical and recent clinical trial evidence on lipoprotein heterogeneity.
• Analysis of the link between LDL composition, size, and coronary heart disease (CHD) risk.
• Investigation into the impact of LDL heterogeneity measurement on CHD risk prediction and patient outcomes.

Main Results:

• Lipoprotein heterogeneity is a significant factor in residual CVD risk.
• Differences in LDL subclass distribution are associated with CHD risk and disease progression.
• Recent evidence supports the clinical relevance of LDL heterogeneity measurement for risk stratification.

Conclusions:

• Assessing lipoprotein heterogeneity improves the prediction of CHD risk.
• Determination of LDL subclass distribution aids in guiding appropriate therapeutic interventions.
• Measuring lipoprotein heterogeneity is crucial for managing residual CVD risk in patients on statin therapy.